Investigation Report on China Imatinib Mesylate Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||332301|
|出版日期||內容資訊||英文 20 Pages
|imatinib mesylate的中國市場 Investigation Report on China Imatinib Mesylate Market, 2010-2019|
|出版日期: 2015年06月04日||內容資訊: 英文 20 Pages||
The mortality of leukemia ranks sixth among tumors while its incidence and mortality ranks first among malignant tumors for teenagers. The incidence of leukemia reaches two age peaks: 0-9 years old and above 60 years old.
Imatinib Mesylate was a tyrosine kinase inhibitor developed by Novartis. On May. 10, 2001, Imatinib Mesylate got FDA's express approval with the trade name of Gleevec due to its groundbreaking anti-tumor mechanism. On Dec. 23, 2009, Imatinib Mesylate gained its status as the first-line treatment for chronic myelogenous leukemia under FDA's approval. And now it has been approved for treatment of chronic myelogenous leukemia in more than 80 countries around the world.
After entering Chinese market on Apr. 17, 2002, Imatinib Mesylate has developed fast with annual sales reaching CNY 532 million in 2014 and CAGR reaching up to 42% during the period of 2005-2014. Currently, Imatinib Mesylate in the Chinese market is made by the following three companies: Novartis (Swiss), Chia Tai Tianqing Pharmaceutical Group Co., Ltd and Hansoh Pharmaceutical, among which Novartis has the largest market share of over 98% with sales value reaching up to CNY 523 million in 2014.
Imatinib Mesylate has accurate curative effects on chronic myelogenous leukemia despite its relatively high price. Chinese patients with low incomes were once sued for purchasing Imatinib Mesylate smuggled from India whose price is only 10% or less of that in Chinese market. As China's economy develops, people's income and purchasing power increases. Since an increasing number of patients are estimated to afford Imatinib Mesylate, its market size will expand further in China.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report:
Hansoh Pharmaceutical; Chia Tai Tianqing Pharmaceutical Group Co., LtdNovartis